Drugsupdate.com is up for sale. To own one of the most recognized online brands by doctors in India with millions of visitors - click here.

logo image
news images

FDA Approves laViv (azficel-T);Fibrocell Science

04-Dec-2011

 

For the improvement of nasolabial fold wrinkles in adults by Fibrocell Science; Approved June 2011

 

General Information

LaViv (azficel-T) is an autologous cellular product. Collagen-producing fibroblast cells are harvested from the skin behind the ear. The fibroblasts from this tissue sample are cultured and allowed to multiply, so they can be injected to treat appropriate dermal targets. The exact mechanism of action is unknown.

laViv is specifically indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.

laViv is for autologous intradermal injection only. The recommended treatment regimen is three treatment sessions, administering up to 2 milliliters (2 vials) of laViv per session, at three to six week intervals.

 

Side Effects

Adverse events associated with the use of laViv may include, but are not limited to, the following:

  • injection-site redness
  • bruising
  • swelling
  • pain
  • hemorrhage
  • edema
  • nodules
  • papules
  • irritation
  • dermatitis
  • pruritus

 

Mechanism of Action

LaViv (azficel-T) is an autologous cellular product. Collagen-producing fibroblast cells are harvested from the skin behind the ear. The fibroblasts from this tissue sample are cultured and allowed to multiply, so they can be injected to treat appropriate dermal targets. The exact mechanism of action is unknown.

© 2011-2019 DrugsUpdate.com. Disclaimer | Site Map

Feedback
  • Companies that own platforms will own the market
  • Trusted and recognized by all Doctors
  • Access to Millions of Visitors instantly.
  • Companies that own platforms will own the market
  • Trusted and recognized by all Doctors
  • Access to Millions of Visitors instantly.